Mikael Marttinen

Mikael Marttinen

Auto-generated profile, based on publicly available information

Mikael Marttinen

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
FEFanny Eysert
Fanny Eysert
ACAudrey Coulon
Audrey Coulon
EBEmmanuelle Boscher
Emmanuelle Boscher
AVAnaїs-Camille Vreulx
Anaїs-Camille Vreulx
AFAmandine Flaig
Amandine Flaig
JCJulien Chapuis
Julien Chapuis
Although APP metabolism is being intensively investigated, a large fraction of its modulators is yet to be characterized. In this context, we combined two genome-wide high-content screenings to assess the functional impact of miRNAs and genes on APP metabolism and the signaling pathways involved. This approach highlighted the involvement ofFERMT2(or Kindlin-2), a genetic risk factor of Alzheimer’s disease (AD), as a potential key modulator of axon guidance, a neuronal process that depends on the regulation of APP metabolism. We found that FERMT2 directly interacts with APP to modulate its metabolism, and that FERMT2 underexpression impacts axonal growth, synaptic connectivity, and long-term potentiation in an APP-dependent manner. Last, the rs7143400-T allele, which is associated with an increased AD risk and localized within the 3′UTR of FERMT2, induced a downregulation of FERMT2 expression through binding of miR-4504 among others. This miRNA is mainly expressed in neurons and significantly overexpressed in AD brains compared to controls. Altogether, our data provide strong evidence for a detrimental effect of FERMT2 underexpression in neurons and insight into how this may influence AD pathogenesis.

26 May 2025 in Nature Methods
Verified
Journal Article
Open access
PDF file
SLSara Lobato-Moreno
Sara Lobato-Moreno
UYUmut Yildiz
Umut Yildiz
ACAnnique Claringbould
Annique Claringbould
NSNila H. Servaas
Nila H. Servaas
EVEvi P. Vlachou
Evi P. Vlachou
JZJudith B. Zaugg
Judith B. Zaugg
Enhancers and transcription factors (TFs) are crucial in regulating cellular processes. Current multiomic technologies to study these elements in gene regulatory mechanisms lack multiplexing capability and scalability. Here we present single-cell ultra-high-throughput multiplexed sequencing (SUM-seq) for co-assaying chromatin accessibility and gene expression in single nuclei. SUM-seq enables profiling hundreds of samples at the million cell scale and outperforms current high-throughput single-cell methods. We demonstrate the capability of SUM-seq to (1) resolve temporal gene regulation of macrophage M1 and M2 polarization to bridge TF regulatory networks and immune disease genetic variants, (2) define the regulatory landscape of primary T helper cell subsets and (3) dissect the effect of perturbing lineage TFs via arrayed CRISPR screens in spontaneously differentiating human induced pluripotent stem cells. SUM-seq offers a cost-effective, scalable solution for ultra-high-throughput single-cell multiomic sequencing, accelerating the unraveling of complex gene regulatory networks in cell differentiation, responses to perturbations and disease studies.

1 September 2025 in Nature Methods
Verified
Journal Article
Open access
PDF file
DLDominik Lindenhofer
Dominik Lindenhofer
JBJulia R. Bauman
Julia R. Bauman
JHJohn A. Hawkins
John A. Hawkins
DFDonnacha Fitzgerald
Donnacha Fitzgerald
UYUmut Yildiz
Umut Yildiz
LSLars M. Steinmetz
Lars M. Steinmetz
Genetic variants (both coding and noncoding) can impact gene function and expression, driving disease mechanisms such as cancer progression. The systematic study of endogenous genetic variants is hindered by inefficient precision editing tools, combined with technical limitations in confidently linking genotypes to gene expression at single-cell resolution. We developed single-cell DNA–RNA sequencing (SDR-seq) to simultaneously profile up to 480 genomic DNA loci and genes in thousands of single cells, enabling accurate determination of coding and noncoding variant zygosity alongside associated gene expression changes. Using SDR-seq, we associate coding and noncoding variants with distinct gene expression in human induced pluripotent stem cells. Furthermore, we demonstrate that in primary B cell lymphoma samples, cells with a higher mutational burden exhibit elevated B cell receptor signaling and tumorigenic gene expression. SDR-seq provides a powerful platform to dissect regulatory mechanisms encoded by genetic variants, advancing our understanding of gene expression regulation and its implications for disease.

9 September 2015 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
TSTimo Sarajärvi
Timo Sarajärvi
MMMikael Marttinen
Mikael Marttinen
TNTeemu Natunen
Teemu Natunen
TKTarja Kauppinen
Tarja Kauppinen
PMPetra Mäkinen
Petra Mäkinen
Mikko HiltunenMikko Hiltunen
Mikko Hiltunen
The agonist-induced activation of human δ -opioid receptor (δ OR) has been shown to increase β- (BACE1) and γ -secretase activities leading to increased production of amyloid-β (Aβ) peptide. We have recently shown that phenylalanine to cysteine subst

4 January 2021 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
FEFanny Eysert
Fanny Eysert
ACAudrey Coulon
Audrey Coulon
EBEmmanuelle Boscher
Emmanuelle Boscher
AVAnaїs-Camille Vreulx
Anaїs-Camille Vreulx
AFAmandine Flaig
Amandine Flaig
JCJulien Chapuis
Julien Chapuis
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

26 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SLSara Lobato-Moreno
Sara Lobato-Moreno
UYUmut Yildiz
Umut Yildiz
ACAnnique Claringbould
Annique Claringbould
NSNila H. Servaas
Nila H. Servaas
EVEvi P. Vlachou
Evi P. Vlachou
JZJudith B. Zaugg
Judith B. Zaugg
Enhancers and transcription factors (TFs) are crucial in regulating cellular processes, including disease-associated cell states. Current multiomic technologies to study these elements in gene regulatory mechanisms lack multiplexing capability and scalability. Here, we present SUM-seq, a cost-effective, scalable S ingle-cell U ltra-high-throughput M ultiomic sequencing method for co-assaying chromatin accessibility and gene expression in single nuclei. SUM-seq enables profiling hundreds of samples at the million cell scale and outperforms current high-throughput single-cell methods. We applied SUM-seq to dissect the gene regulatory mechanisms governing macrophage polarization and explored their link to traits from genome-wide association studies (GWAS). Our analyses confirmed known TFs orchestrating M1 and M2 macrophage programs, unveiled key regulators, and demonstrated extensive enhancer rewiring. Integration with GWAS data further pinpointed the impact of specific TFs on a set of immune traits. Notably, inferred enhancers regulated by the STAT1/STAT2/IRF9 (ISGF3) complex were enriched for genetic variants associated with Crohn’s disease, ulcerative colitis and multiple sclerosis, and their target genes included known drug targets. This highlights the potential of SUM-seq for dissecting molecular disease mechanisms. SUM-seq offers a cost-effective, scalable solution for ultra-high-throughput single-cell multiomic sequencing, excelling in unraveling complex gene regulatory networks in cell differentiation, responses to perturbations, and disease studies.